Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
Antonino Carbone, Annunziata Gloghini, Giancarlo Pruneri, Riccardo Dolcetti
Cancer Medicine | WILEY | Published : 2019
Immune checkpoint-blocking antibodies have therapeutic activity against relapsed or progressive classic Hodgkin lymphoma (cHL), but Hodgkin Reed-Sternberg cells can develop resistance to this therapy via multiple mechanisms. To improve the efficacy of immune checkpoint blockade, we need a more precise understanding of the immune escape mechanisms active in individual cHL patients, and this requires a detailed characterization of immune cell populations in the tumor microenvironment. These cell-cell interactions can now be studied by multiplex immunohistochemistry coupled to digital image analysis. This method should allow the identification of actionable target molecules mediating resistance..View full abstract
This work was supported in part by an Institutional grant from Centro di Riferimento Oncologico di Aviano (CRO) IRCCS (A. C.) and from an Institutional grant from Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano "Visualizing immunomodulatory molecules in individual human cancer cells using in situ bright field multiplexing methods and an innovative proximity detection assay" (A. G.).